Aug 12
STRO · Sutro Biopharma, Inc.
$9.20
-0.74 (-7.44%)
At close · Nov 5
Return incl. dividend (before tax)
Market Cap
$153.71M
Shares
16.58M
Volume · Nov 5
771.86K
Avg daily vol (3M)
319.6K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.20
Open$9.93
Day$8.90–9.93
52W close$7.30–40.91
Avg vol 30d318K
Short int2.0M · 11.8% of shares · 6.3d
Short vol10%
Last earningsAug 12, 2026
DataJan 2020–Nov 2026
Filing10-Q · Aug 12
Up next
Nov 11, 2026
Est · unconfirmed
· in 1 wks
Latest documents
2026
Aug 12
Quarterly report
10-Q
FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2
AI summary on its way
Revenue $9.84M
▼ 84.6%
Net loss $38.53M
Diluted EPS -$2.33
Jun 8
Jun 5
Jun 4
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$45.70M
Trailing 12 months
Net income (TTM)
−$180.64M
Trailing 12 months
Revenue growth YoY
-84.6%
Year over year
Operating margin
-319.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+94.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
11.8%
Latest settlement · 6.3 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 28.2 · fear
Equity put/call 0.44
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−60%
below
Price vs 50-day avg
−36%
below
RSI (14)
31
neutral
MACD trend
Positive
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−40%
trailing
6-month return
−76%
trailing
YTD return
−20%
this year
Relative strength
−76%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $23 — 200d above 50d
Institutional flow
Distributing
19 of 100 funds reported for Sep 30 · net -30.1K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.83% of shares out · ▲ +6.1% MoM · 6.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
100 holders — mid 3-yr range
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
−26%
Y/Y
EPS growth
+24%
Y/Y
Free cash flow
$-178.8M
Balance sheet
$65.2M
net cash
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
10.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−60%
Bearish
Price vs 50-day avg
−36%
Bearish
RSI (14)
31
Neutral
MACD trend
Positive
Bullish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $23 — 200d above 50d
Institutional flow
Distributing
19 of 100 funds reported for Sep 30 · net -30.1K sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.83% of shares out · ▲ +6.1% MoM · 6.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
100 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $9 · 6%
Range high $41
vs 200-day avg -60%
vs 50-day avg -36%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STRO
this stock
Sutro Biopharma, Inc.
|
$153.71M | -20.5% | -25.7% | — | 11.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$137.54B | +19.7% | +46.2% | 34.9 | 1.7% |
|
MRNA
Moderna, Inc.
|
$103.15B | +718.8% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$94.43B | +17.0% | +20.8% | 20.2 | 2.1% |
|
CSLLY
Csl Ltd
|
$67.11B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STRO | +0.7% | -40.0% | -76.4% | +1.1% | -20.5% |
| SPY | -4.7% | -5.3% | -0.8% | -3.0% | +7.5% |
| vs SPY | +5.4% | -34.7% | -75.6% | +4.1% | -28.0% |
Key facts
CIK
1382101
CUSIP
869367201
13F (30d)
31 filings
19 filers
Visit website
Investor relations